Citadel Advisors’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Citadel Advisors’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,224	Closed	-$7.88K	–	15972
2022 Q4	$7.88K	Buy	11,224 +6,912	+160%	+$11.2K	﹤0.01%	13789
2022 Q3	$12K	Buy	+4,312	New	+$16.3K	﹤0.01%	12240
2022 Q2	–	Sell	-7,037	Closed	-$50K	–	14603
2022 Q1	$50K	Buy	+7,037	New	+$40.9K	﹤0.01%	12791
2021 Q3	–	Sell	-5,207	Closed	-$97K	–	14983
2021 Q2	$97K	Buy	+5,207	New	+$97.1K	﹤0.01%	12946
2019 Q1	–	Sell	-179	Closed	-$6K	–	10071
2018 Q4	$6K	Sell	179 -42	-19%	-$3.54K	﹤0.01%	8979
2018 Q3	$34K	Buy	+221	New	+$32.7K	﹤0.01%	8896
2017 Q1	–	Sell	-122	Closed	-$25K	–	8210
2016 Q4	$25K	Buy	+122	New	+$27.7K	﹤0.01%	7036
2016 Q3	–	Sell	-100	Closed	-$30K	–	7930
2016 Q2	$30K	Buy	+100	New	+$35.2K	﹤0.01%	6524

Other funds holding VYNT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's VYNT Position: Q1 2023 in Review

Citadel Advisors sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2023, closing a stake of 11,224 shares — an estimated $7.88K sold.

Citadel Advisors first reported a position in VYNT in Q2 2016 and held it in 8 quarters. The position peaked at $97K in Q2 2021. 17 funds tracked by Wall St. Rank hold VYNT as of Q1 2023.

Citadel Advisors reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 11,224 Vyant Bio, Inc. Common Stock shares in Q1 2023, an estimated $7.88K.
Citadel Advisors first reported a position in Vyant Bio, Inc. Common Stock in Q2 2016 and held it in 8 quarters.
Citadel Advisors's Vyant Bio, Inc. Common Stock position peaked at $97K in Q2 2021.
17 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.